Orient Pharma Co (ROCO:4166) E10: NT$-0.80 (As of Dec. 2025)


ROCO:4166 Orient Pharma Co Ltd ROCO:4166
56 GF Score
Price NT$27.20
GF Value NT$45.09
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Orient Pharma Co E10?

Orient Pharma Co ROCO:4166 +5.02% 56 E10 is NT$-0.80 as of Dec. 2025. GuruFocus rates ROCO:4166 with a GF Score™ of 56/100 and a GF Value™ of NT$45.09 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Orient Pharma Co's adjusted earnings per share data for the fiscal year that ended in Dec. 2025 was NT$0.900. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is NT$-0.80 for the trailing ten years ended in Dec. 2025.

During the past 3 years, the average E10 Growth Rate was 14.70% per year. During the past 5 years, the average E10 Growth Rate was 9.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Orient Pharma Co was 14.70% per year. The lowest was 1.50% per year. And the median was 5.95% per year.

As of today (2026-07-07), Orient Pharma Co's current stock price is NT$ 27.20. Orient Pharma Co's E10 for the fiscal year that ended in Dec. 2025 was NT$-0.80. Orient Pharma Co's Shiller PE Ratio of today is .


Orient Pharma Co  (ROCO:4166) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Orient Pharma Co E10 Related Terms


Orient Pharma Co E10 Historical Data

* Premium members only.

The historical data trend for Orient Pharma Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Pharma Co E10 Chart

Orient Pharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.34 -1.29 -1.18 -1.06 -0.80

Orient Pharma Co Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.06 0.00 0.00 0.00 -0.80

ROCO:4166 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orient Pharma Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Orient Pharma Co's Shiller PE Ratio falls into.


ROCO:4166
56GF Score
Orient Pharma Co Ltd ROCO:4166
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Pharma Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orient Pharma Co's adjusted earnings per share data for the fiscal year that ended in Dec. 2025 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.9/324.0540*324.0540
=0.900

Current CPI (Dec. 2025) = 324.0540.

Orient Pharma Co Annual Data

per_share_eps CPI Adj_EPS
201612 -1.464 241.432 -1.965
201712 -1.933 246.524 -2.541
201812 -1.026 251.233 -1.323
201912 -1.290 256.974 -1.627
202012 -1.012 260.474 -1.259
202112 -0.550 278.802 -0.639
202212 -0.154 296.797 -0.168
202312 0.100 306.746 0.106
202412 0.480 315.605 0.493
202512 0.900 324.054 0.900

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of NT$-0.80 mean?
Orient Pharma Co (ROCO:4166) has a E10 of NT$-0.80 as of Dec. 2025. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Orient Pharma Co and its competitors.
Is Orient Pharma Co's E10 too high?
Orient Pharma Co's current E10 is NT$-0.80. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's E10 compare to ZTS and UTHR?
Orient Pharma Co's E10 of NT$-0.80 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Orient Pharma Co and its competitors. Orient Pharma Co's current E10 is NT$-0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current E10 is NT$-0.80. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current E10 is NT$-0.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • E10: NT$-0.80
  • GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score

Get the complete analysis for ROCO:4166

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.20
Price
NT$45.09
GF Value